PMID- 38191139
OWN - NLM
STAT- MEDLINE
DCOM- 20240110
LR  - 20240110
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 76
IP  - 1
DP  - 2024 Jan
TI  - [Pathogenesis of MuSK Antibody-positive Myasthenia Gravis].
PG  - 47-53
LID - 10.11477/mf.1416202557 [doi]
AB  - Long-term remission is rare in patients with myasthenia gravis (MG), and 
      health-related quality of life is lower in patients with MG than in healthy 
      individuals. Approximately 5% of patients with MG show positive results on 
      muscle-specific kinase (MuSK) antibody testing and usually have severe symptoms, 
      refractory disease, residual muscle atrophy, and poor prognosis. Recent studies 
      that have investigated the pathogenesis of MuSK antibody-positive MG have 
      reported contributors to treatment refractoriness in cases of MG. In this 
      article, we review the most recent findings.
FAU - Shigemoto, Kazuhiro
AU  - Shigemoto K
AD  - Tokyo Metropolitan Institute for Geriatrics and Gerontology.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Humans
MH  - *Quality of Life
MH  - Muscular Atrophy
MH  - *Myasthenia Gravis
EDAT- 2024/01/09 00:42
MHDA- 2024/01/10 06:42
CRDT- 2024/01/08 19:53
PHST- 2024/01/10 06:42 [medline]
PHST- 2024/01/09 00:42 [pubmed]
PHST- 2024/01/08 19:53 [entrez]
AID - 1416202557 [pii]
AID - 10.11477/mf.1416202557 [doi]
PST - ppublish
SO  - Brain Nerve. 2024 Jan;76(1):47-53. doi: 10.11477/mf.1416202557.